| Country | BRCA1 mutations | BRCA2 mutations | Founder mutations |
| Singapore | Exon 13 dup, 13–15 del [205], c.2845insA [206] | Exons 4–11 dup [205] | c.2845insA [206] | Malaysia | c.2845insA [206], 4427T>C, 2846insA, 2201C>T and 4956A>G (79%), 3668A>G [207], 2731C>T, 3232A.G, 3667A.G [24], exon 3 dup [108]
| 4859delA, 4265delCT [208], 1342C.A [24] 490 delCT | c.2845insA [206] | Pakistan | 4627C>A (22%) [107], 4184del4 (15%), 185delAG and 2080insA and IVS14−1G>A (11%), 2041insA and 4284delAG (8%), 3889delAG and 2388delG (7%) [106] | 3337C>T (50%), 5057delTG (50%) [106] | 4627C>A, 185delAG, 185insA [107] | Iran
| g.-1075C>G, g.-235A>G g.-134T>C, g.442−34C>T, g.548–58delT c.2077G>A, c.2082C>T c.2311T>C, c.2612C>T c.3113A>G, c.3119G>A c.3548A>G, c.4308T>C c.4837A>G, g.4987−68A>G, g.4987−92A>G g.5075−53C>T, g.5152+66G>A g.381_389del9ins29 g. 421G>T, g. 1286C>T [34] IVS16−92A>G, IVS16−68A>G, 4837A>G, IVS18+65G>A [133], Tyr978X,
| g.-1235G>A, g.-26G>A g.681+56C>T, c.865A>C c.1114A>C, c.1365A>G c.2229T>C, c.2971A>G c.3396A>G, c.3516G>A c.3807T>C c.4415_4418delAGAA c.5529A>C, c.6033_6034insGT c.7242A>G, g.7435+53C>T g.7806−14T>C g.8755−66T>C [34] c.4415-4418delAGAA and c.6033insGT [134] c.5576_5579delTTAA c.9485−1G>A [209] | —
| Lebanon | IVS17−53C>T and g.381-389del9ins29 [134], 5382insC [138] G2031T [135] | — | — | India | 185delAG [122, 123], 2983C>A, 3450delCAAG [123, 124], c.3548A>G, c.-26G>A, c.317-54C>G [125], 5341T>G, 5364C>G, 5379 G>T [210] 1014DelGT and 3889DelAG [126] 5382insC [127] | — | 185delAG [122]
| Sri Lanka | c.3086delT, c.5404delG, c.856T>G, IVS17−2A>T [23] | — | — | Philippines | 5454delC [208] | 4265delCT and 4859delA [208] | 5454delC, 4265delCT, 4859delA [208] | Indonesia (in South eastern Asia) | — | 6775G>T, p.Glu2183X, c.2699_2704delTAAATG [211] | c.2699_2704delTAAATG [211] | Vietnam | 185insA [212] | 4706delAAAG [212] | — | Thailand
| 3300delA [202]
| —
| — | Israel (in Western Asia) | 185delAG, Tyr978X, A1708E, 981delAT, C61G [141] | R2336P, IVS2+1G>A, 8765delAG [141] | — |
|
|